UCB reported that its IL‑17A/F antibody Bimzelx achieved statistically significant superiority to AbbVie’s IL‑23 inhibitor Skyrizi in a head‑to‑head psoriatic arthritis trial, the first time an approved biologic showed superiority over an IL‑23 blocker in this indication. The result raises competitive pressure on AbbVie’s immunology franchise and could reshape positioning in psoriatic disease markets. Analysts note clinical superiority may not translate immediately into market share shifts without broader safety, dosing, and long‑term data; still, the head‑to‑head win strengthens UCB’s late‑stage immunology narrative and will factor into payer and guideline considerations.